• 4.20, 2010

  R&D

  UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial

• 4.16, 2010

  Manufacturing

  API and UMN Pharma Announce Formulation Process Collaboration

• 1.26, 2010

  Manufacturing

  IHI Corporation and UMN Pharma Announce Manufacturing Collaboration

Top of Page

• 10.05, 2009

  R&D

  UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.

• 6.29, 2009

  Others

  Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine.

• 2.16, 2009

  Manufacturing

  UMN Pharma Secures additional investment from IPEC.

• 2.13, 2009

  R&D

  UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.

• 1.15, 2009

  R&D

  UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.

Top of Page

• 12.22, 2008

  Others

  Relocation of Tokyo Head Office to Yokohama. Renamed as Yokohama Head Office.

• 10.01, 2008

  R&D

  UMN-02 pharmacological study results published in the Journal of Pharmacology and Experimental Therapeutics.

• 8.22, 2008

  Manufacturing

  UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.

• 6.18, 2008

  R&D

  UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

• 6.10, 2008

  R&D

  UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.

• 5.19, 2008

  R&D

  UMN Pharma presents at DIGESTIVE DESEASE WEEK 2008 in San Diego, California.

• 4.30, 2008

  Manufacturing

  UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.

• 4.10, 2008

  R&D

  UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.

Top of Page

• 10.27, 2007

  R&D

  The results of a pharmacological study on UMN-02 published in the Journal of Pharmacological Sciences.

• 10.26, 2007

  R&D

  UMN Pharma is awarded the research fund "Potentiality Verification Stage" sponsored by Japan Science and Technology Agency.

• 4.17, 2007

  R&D

  UMN Pharma makes presentation at the annual meeting of the American Association for Cancer Research (AACR) held in Los Angeles, California in 2007.

• 4.11, 2007

  R&D

  The result of a clinical study of FluBlØk (UMN-05) in the US is published in JAMA (The Journal of The American Medical Association).

• 3.15, 2007

  R&D

  UMN Pharma makes a presentation at the annual meeting of the Japanese Pharmacological Sciences held in Nagoya in 2007.

• 2.21, 2007

  Finance & Alliance

  UMN Pharma completes $18.9 million Series C financing round, with participation of 20 investors.

Top of Page

• 8.29, 2006

  Finance & Alliance

  UMN Pharma signs a license agreement of UMN-05 with Protein Sciences Corporation.

• 2.03, 2006

  Finance & Alliance

  UMN Pharma completes $7.5 million Series B-2 financing round, with participation of 11 investors.

Top of Page

• 10.17, 2005

  Finance & Alliance

  UMN Pharma completes $1.1 million Series B-1 financing round, with participation of 3 venture capital firms.

• 7.22, 2005

  Finance & Alliance

  UMN Pharma completes $0.9 million Series A round (second tranche), with participation of 2 venture capital firms.

Top of Page

• 12.31, 2004

  Finance & Alliance

  UMN Pharma completes $0.9 million Series A round (first tranche), with participation of 2 venture capital firms.

Top of Page